意大利乳腺癌治疗技术现状的综合评价

Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48.
[http://dx.doi.org/10.3322/caac.21763] [PMID: 36633525]

Iacopetta, D.; Ceramella, J.; Baldino, N.; Sinicropi, M.; Catalano, A. Targeting breast cancer: An overlook on current strategies. Int. J. Mol. Sci., 2023, 24(4), 3643.
[http://dx.doi.org/10.3390/ijms24043643] [PMID: 36835056]

Tarantino, P.; Viale, G.; Press, M.F.; Hu, X.; Penault-Llorca, F.; Bardia, A.; Batistatou, A.; Burstein, H.J.; Carey, L.A.; Cortes, J.; Denkert, C.; Diéras, V.; Jacot, W.; Koutras, A.K.; Lebeau, A.; Loibl, S.; Modi, S.; Mosele, M.F.; Provenzano, E.; Pruneri, G.; Reis-Filho, J.S.; Rojo, F.; Salgado, R.; Schmid, P.; Schnitt, S.J.; Tolaney, S.M.; Trapani, D.; Vincent-Salomon, A.; Wolff, A.C.; Pentheroudakis, G.; André, F.; Curigliano, G. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann. Oncol., 2023, 34(8), 645-659.
[http://dx.doi.org/10.1016/j.annonc.2023.05.008] [PMID: 37269905]

Agostinetto, E.; Rediti, M.; Fimereli, D.; Debien, V.; Piccart, M.; Aftimos, P.; Sotiriou, C.; de Azambuja, E. HER2-low breast cancer: Molecular characteristics and prognosis. Cancers, 2021, 13(11), 2824.
[http://dx.doi.org/10.3390/cancers13112824] [PMID: 34198891]

Zhang, H.; Peng, Y. Current biological, pathological and clinical landscape of HER2-low breast cancer. Cancers, 2022, 15(1), 126.
[http://dx.doi.org/10.3390/cancers15010126] [PMID: 36612123]

D’Arienzo, A.; Verrazzo, A.; Pagliuca, M.; Napolitano, F.; Parola, S.; Viggiani, M.; Caputo, R.; Puglisi, F.; Giuliano, M.; Del Mastro, L.; Arpino, G.; De Laurentiis, M.; Montemurro, F. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine, 2023, 62, 102113.
[http://dx.doi.org/10.1016/j.eclinm.2023.102113] [PMID: 37554126]

Shyam Sunder, S.; Sharma, U.C.; Pokharel, S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduct. Target. Ther., 2023, 8(1), 262.
[http://dx.doi.org/10.1038/s41392-023-01469-6] [PMID: 37414756]

Tarantino, P.; Corti, C.; Schmid, P.; Cortes, J.; Mittendorf, E.A.; Rugo, H.; Tolaney, S.M.; Bianchini, G.; Andrè, F.; Curigliano, G. Immunotherapy for early triple negative breast cancer: Research agenda for the next decade. NPJ Breast Cancer, 2022, 8(1), 23.
[http://dx.doi.org/10.1038/s41523-022-00386-1] [PMID: 35181659]

Heins, M.J.; de Ligt, K.M.; Verloop, J.; Siesling, S.; Korevaar, J.C.; Berendsen, A.; Brandenbarg, D.; Dassen, A.; Jager, A.; Hugtenburg, J.; Weele, G. Adverse health effects after breast cancer up to 14 years after diagnosis. Breast, 2022, 61, 22-28.
[http://dx.doi.org/10.1016/j.breast.2021.12.001] [PMID: 34891036]

Boszkiewicz, K.; Piwowar, A.; Petryszyn, P. Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients - A systematic review and meta-analysis. J. Clin. Med., 2022, 11(11), 3133.
[http://dx.doi.org/10.3390/jcm11113133] [PMID: 35683517]

Lemij, A.A.; de Glas, N.A.; Derks, M.G.M.; Bastiaannet, E.; Merkus, J.W.S.; Lans, T.E.; van der Pol, C.C.; van Dalen, T.; Vulink, A.J.E.; van Gerven, L.; Guicherit, O.R.; Linthorst-Niers, E.M.H.; van den Bos, F.; Kroep, J.R.; Liefers, G.J.; Portielje, J.E.A. Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. Breast Cancer Res. Treat., 2022, 193(3), 567-577.
[http://dx.doi.org/10.1007/s10549-022-06583-7] [PMID: 35441273]

Keane, D.; Phillips, G.; Mitchell, N.; Connolly, R.M.; Hegarty, J. Improving quality of life and symptom experience in patients with metastatic breast cancer: A systematic review of supportive care interventions. Psychooncology, 2023, 32(8), 1192-1207.
[http://dx.doi.org/10.1002/pon.6183] [PMID: 37434307]

Sun, H.; Xu, J.; Dai, S.; Ma, Y.; Sun, T. Breast cancer brain metastasis: Current evidence and future directions. Cancer Med., 2023, 12(2), 1007-1024.
[http://dx.doi.org/10.1002/cam4.5021] [PMID: 35822637]

Farahani, M.K.; Gharibshahian, M.; Rezvani, A.; Vaez, A. Breast cancer brain metastasis: From etiology to state-of-the-art modeling. J. Biol. Eng., 2023, 17(1), 41.
[http://dx.doi.org/10.1186/s13036-023-00352-w] [PMID: 37386445]

Vega Cano, K.S.; Marmolejo Castañeda, D.H.; Escrivá-de-Romaní, S.; Saura, C. Systemic therapy for HER2-positive metastatic breast cancer: Current and future trends. Cancers, 2022, 15(1), 51.
[http://dx.doi.org/10.3390/cancers15010051] [PMID: 36612047]

Simion, L.; Augustin, I.G.; Volovat, S.R.; Froicu, E.M.; Schenker, M.; Mazilu, L.; Nitipir, C.; Zivari, M.; Volovat, C.; Alecu, M.; Tanase, B.; Cirimbei, C.; Luca, D.C.; Stanculeanu, D.L.; Zob, D.L. HER2 positive breast cancer therapy - A challenging and continuously moving pathway – A narrative literature review. Arch Breast Cancer., 2022, 10(1), 15-25.
[http://dx.doi.org/10.32768/abc.202310115-25]

von Arx, C.; De Placido, P.; Caltavituro, A.; Di Rienzo, R.; Buonaiuto, R.; De Laurentiis, M.; Arpino, G.; Puglisi, F.; Giuliano, M.; Del Mastro, L. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat. Rev., 2023, 113, 102500.
[http://dx.doi.org/10.1016/j.ctrv.2022.102500] [PMID: 36587473]

Gion, M.; Trapani, D.; Cortés, A.; Valenza, C.; Lin, N.; Cortés, J.; Curigliano, G. Systemic therapy for HER2-positive metastatic breast cancer: Moving into a new era. Am. Soc. Clin. Oncol. Educ. Book, 2022, 42(42), 82-92.
[http://dx.doi.org/10.1200/EDBK_351222] [PMID: 35671434]

Agostinetto, E.; Montemurro, F.; Puglisi, F.; Criscitiello, C.; Bianchini, G.; Del Mastro, L.; Introna, M.; Tondini, C.; Santoro, A.; Zambelli, A. Immunotherapy for HER2-positive breast cancer: Clinical evidence and future perspectives. Cancers, 2022, 14(9), 2136.
[http://dx.doi.org/10.3390/cancers14092136] [PMID: 35565264]

Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med., 2007, 357(1), 39-51.
[http://dx.doi.org/10.1056/NEJMra043186] [PMID: 17611206]

Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. Food and Drug Administration, 2014, Available from: https://www.fda.gov/downloads/drugs/guidances/ucm305501.pdf

Howie, L.J.; Scher, N.S.; Amiri-Kordestani, L.; Zhang, L.; King-Kallimanis, B.L.; Choudhry, Y.; Schroeder, J.; Goldberg, K.B.; Kluetz, P.G.; Ibrahim, A.; Sridhara, R.; Blumenthal, G.M.; Pazdur, R.; Beaver, J.A. FDA approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin. Cancer Res., 2019, 25(10), 2949-2955.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-3003] [PMID: 30552112]

Krop, I.E.; Kim, S.B.; Martin, A.G.; LoRusso, P.M.; Ferrero, J.M.; Badovinac-Crnjevic, T.; Hoersch, S.; Smitt, M.; Wildiers, H. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol., 2017, 18(6), 743-754.
[http://dx.doi.org/10.1016/S1470-2045(17)30313-3] [PMID: 28526538]

Baselga, J.; Lewis Phillips, G.D.; Verma, S.; Ro, J.; Huober, J.; Guardino, A.E.; Samant, M.K.; Olsen, S.; de Haas, S.L.; Pegram, M.D. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin. Cancer Res., 2016, 22(15), 3755-3763.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2499] [PMID: 26920887]

Diéras, V.; Miles, D.; Verma, S.; Pegram, M.; Welslau, M.; Baselga, J.; Krop, I.E.; Blackwell, K.; Hoersch, S.; Xu, J.; Green, M.; Gianni, L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol., 2017, 18(6), 732-742.
[http://dx.doi.org/10.1016/S1470-2045(17)30312-1] [PMID: 28526536]

Cortés, J.; Kim, S.B.; Chung, W.P.; Im, S.A.; Park, Y.H.; Hegg, R.; Kim, M.H.; Tseng, L.M.; Petry, V.; Chung, C.F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Huang, C.S.; Kim, J.H.; Chiu, J.W.Y.; Pedrini, J.L.; Lee, C.; Liu, Y.; Cathcart, J.; Bako, E.; Verma, S.; Hurvitz, S.A. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med., 2022, 386(12), 1143-1154.
[http://dx.doi.org/10.1056/NEJMoa2115022] [PMID: 35320644]

Hurvitz, S.A.; Hegg, R.; Chung, W-P.; Im, S.A.; Jacot, W.; Ganju, V. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet, 2022, 401, 105-117.

Perez, E.A.; Barrios, C.; Eiermann, W.; Toi, M.; Im, Y.H.; Conte, P.; Martin, M.; Pienkowski, T.; Pivot, X.B.; Burris, H.A., III; Petersen, J.A.; De Haas, S.; Hoersch, S.; Patre, M.; Ellis, P.A. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125(22), 3974-3984.
[http://dx.doi.org/10.1002/cncr.32392] [PMID: 31318460]

Yuan, Y.; Liu, X.; Cai, Y.; Li, W. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PLoS One, 2023, 18(1), e0279775.
[http://dx.doi.org/10.1371/journal.pone.0279775] [PMID: 36602979]

Saura, C.; Oliveira, M.; Feng, Y.H.; Dai, M.S.; Chen, S.W.; Hurvitz, S.A.; Kim, S.B.; Moy, B.; Delaloge, S.; Gradishar, W.; Masuda, N.; Palacova, M.; Trudeau, M.E.; Mattson, J.; Yap, Y.S.; Hou, M.F.; De Laurentiis, M.; Yeh, Y.M.; Chang, H.T.; Yau, T.; Wildiers, H.; Haley, B.; Fagnani, D.; Lu, Y.S.; Crown, J.; Lin, J.; Takahashi, M.; Takano, T.; Yamaguchi, M.; Fujii, T.; Yao, B.; Bebchuk, J.; Keyvanjah, K.; Bryce, R.; Brufsky, A. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2- positive metastatic breast cancer previously treated with ≥ 2 HER2- directed regimens: Phase III NALA trial. J. Clin. Oncol., 2020, 38(27), 3138-3149.
[http://dx.doi.org/10.1200/JCO.20.00147] [PMID: 32678716]

Alasmari, M.M. A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer. Cancers, 2022, 15(1), 38.
[http://dx.doi.org/10.3390/cancers15010038] [PMID: 36612034]

Rugo, H.S.; Im, S.A.; Cardoso, F.; Cortés, J.; Curigliano, G.; Musolino, A.; Pegram, M.D.; Wright, G.S.; Saura, C.; Escrivá-de-Romaní, S.; De Laurentiis, M.; Levy, C.; Brown-Glaberman, U.; Ferrero, J.M.; de Boer, M.; Kim, S.B.; Petráková, K.; Yardley, D.A.; Freedman, O.; Jakobsen, E.H.; Kaufman, B.; Yerushalmi, R.; Fasching, P.A.; Nordstrom, J.L.; Bonvini, E.; Koenig, S.; Edlich, S.; Hong, S.; Rock, E.P.; Gradishar, W.J. Efficacy of margetuximab vs. Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol., 2021, 7(4), 573-584.
[http://dx.doi.org/10.1001/jamaoncol.2020.7932] [PMID: 33480963]

Wynn, C.S.; Tang, S.C. Anti-HER2 therapy in metastatic breast cancer: Many choices and future directions. Cancer Metastasis Rev., 2022, 41(1), 193-209.
[http://dx.doi.org/10.1007/s10555-022-10021-x] [PMID: 35142964]

Piezzo, M.; D’Aniello, R.; Avallone, I.; Barba, B.; Cianniello, D.; Cocco, S.; D’Avino, A.; Di Gioia, G.; Di Lauro, V.; Fusco, G.; Piscitelli, R.; von Arx, C.; De Laurentiis, M.; Maiolino, P. Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: A real-world experience from a cancer center. Pharmaceutics, 2021, 13(5), 684.
[http://dx.doi.org/10.3390/pharmaceutics13050684] [PMID: 34068626]

The selection and use of essential medicines: Report of the WHO expert committee on selection and use of essential medicines (Including the 21^st WHO model list of essential medicines and the 7^th WHO model list of essential medicines for children); License: CC BY-NC-SA 3.0 IGO, 2019. Available from: https://apps.who.int/iris/handle/10665/330668 (Accessed on 24 February 2023).

Rugo, H.S.; Linton, K.M.; Cervi, P.; Rosenberg, J.A.; Jacobs, I. A clinician’s guide to biosimilars in oncology. Cancer Treat. Rev., 2016, 46, 73-79.
[http://dx.doi.org/10.1016/j.ctrv.2016.04.003] [PMID: 27135548]

Greco, S.; Fabbri, N.; Spaggiari, R.; De Giorgi, A.; Fabbian, F.; Giovine, A. Update on classic and novel approaches in metastatic triple-negative breast cancer treatment: A comprehensive review. Biomedicines, 2023, 11(6), 1772.
[http://dx.doi.org/10.3390/biomedicines11061772] [PMID: 37371867]

Shi, M.; Li, Z.; Shen, G.; Wang, T.; Li, J.; Wang, M.; Liu, Z.; Zhao, F.; Ren, D.; Zhao, J. Efficacy and safety of first- line treatment for metastatic triple-negative breast cancer: A network meta-analysis. Cancer Pathogen. Ther., 2023.
[http://dx.doi.org/10.1016/j.cpt.2023.06.002]

Won, K.A.; Spruck, C. Triple-negative breast cancer therapy: Current and future perspectives (Review). Int. J. Oncol., 2020, 57(6), 1245-1261.
[http://dx.doi.org/10.3892/ijo.2020.5135] [PMID: 33174058]

Gerratana, L.; Fanotto, V.; Pelizzari, G.; Agostinetto, E.; Puglisi, F. Do platinum salts fit all triple negative breast cancers? Cancer Treat. Rev., 2016, 48, 34-41.
[http://dx.doi.org/10.1016/j.ctrv.2016.06.004] [PMID: 27343437]

Garutti, M.; Pelizzari, G.; Bartoletti, M.; Malfatti, M.C.; Gerratana, L.; Tell, G.; Puglisi, F. Platinum salts in patients with breast cancer: A focus on predictive factors. Int. J. Mol. Sci., 2019, 20(14), 3390.
[http://dx.doi.org/10.3390/ijms20143390] [PMID: 31295913]

Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; Henschel, V.; Molinero, L.; Chui, S.Y.; Funke, R.; Husain, A.; Winer, E.P.; Loi, S.; Emens, L.A. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med., 2018, 379(22), 2108-2121.
[http://dx.doi.org/10.1056/NEJMoa1809615] [PMID: 30345906]

Masuda, J.; Ozaki, Y.; Hara, F.; Kitano, S.; Takano, T. Pembrolizumab plus chemotherapy in triple-negative breast cancer. Lancet, 2021, 398(10294), 24.
[http://dx.doi.org/10.1016/S0140-6736(21)00380-9] [PMID: 34217392]

Carlino, F.; Diana, A.; Piccolo, A.; Ventriglia, A.; Bruno, V.; De Santo, I.; Letizia, O.; De Vita, F.; Daniele, B.; Ciardiello, F.; Orditura, M. Immune-based therapy in triple-negative breast cancer: From molecular biology to clinical practice. Cancers, 2022, 14(9), 2102.
[http://dx.doi.org/10.3390/cancers14092102] [PMID: 35565233]

Mavratzas, A.; Seitz, J.; Smetanay, K.; Schneeweiss, A.; Jäger, D.; Fremd, C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol., 2020, 16(3), 4439-4453.
[http://dx.doi.org/10.2217/fon-2019-0468] [PMID: 31829043]

Schmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kümmel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; Takahashi, M.; Foukakis, T.; Fasching, P.A.; Cardoso, F.; Untch, M.; Jia, L.; Karantza, V.; Zhao, J.; Aktan, G.; Dent, R.; O’Shaughnessy, J. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med., 2020, 382(9), 810-821.
[http://dx.doi.org/10.1056/NEJMoa1910549] [PMID: 32101663]

Valenza, C.; Rizzo, G.; Passalacqua, M.I.; Boldrini, L.; Corti, C.; Trapani, D.; Curigliano, G. Evolving treatment landscape of immunotherapy in breast cancer: Current issues and future perspectives. Ther. Adv. Med. Oncol., 2023, 15
[http://dx.doi.org/10.1177/17588359221146129] [PMID: 36743524]

Capici, S.; Ammoni, L.C.; Meli, N.; Cogliati, V.; Pepe, F.F.; Piazza, F.; Cazzaniga, M.E. Personalised therapies for metastatic triple-negative breast cancer: When target is not everything. Cancers, 2022, 14(15), 3729.
[http://dx.doi.org/10.3390/cancers14153729] [PMID: 35954393]

Trapani, D.; Ferraro, E.; Giugliano, F.; Boscolo Bielo, L.; Curigliano, G.; Burstein, H.J. Postneoadjuvant treatment for triple-negative breast cancer. Curr. Opin. Oncol., 2022, 34(6), 623-634.
[http://dx.doi.org/10.1097/CCO.0000000000000893] [PMID: 35993306]

Catalano, A.; Iacopetta, D.; Ceramella, J.; Mariconda, A.; Rosano, C.; Scumaci, D.; Saturnino, C.; Longo, P.; Sinicropi, M. New achievements for the treatment of triple-negative breast cancer. Appl. Sci., 2022, 12(11), 5554.
[http://dx.doi.org/10.3390/app12115554]

Bravaccini, S.; Maltoni, R. Trop-2 therapy in metastatic triple-negative breast cancer in Italy: Clinical opportunity and regulatory pitfalls. J. Pers. Med., 2021, 11(11), 1211.
[http://dx.doi.org/10.3390/jpm11111211] [PMID: 34834563]

Cortesi, M.; Zanoni, M.; Maltoni, R.; Ravaioli, S.; Tumedei, M.M.; Pirini, F.; Bravaccini, S. TROP2 (trophoblast cell-surface antigen 2): A drug target for breast cancer. Expert Opin. Ther. Targets, 2022, 26(7), 593-602.
[http://dx.doi.org/10.1080/14728222.2022.2113513] [PMID: 35962580]

Miglietta, F.; Griguolo, G.; Bottosso, M.; Giarratano, T.; Lo Mele, M.; Fassan, M.; Cacciatore, M.; Genovesi, E.; De Bartolo, D.; Vernaci, G.; Amato, O.; Porra, F.; Conte, P.; Guarneri, V.; Dieci, M.V. HER2-low-positive breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer, 2022, 8(1), 66.
[http://dx.doi.org/10.1038/s41523-022-00434-w] [PMID: 35595761]

Schlam, I.; Tolaney, S.M.; Tarantino, P. How I treat HER2-low advanced breast cancer. Breast, 2023, 67, 116-123.
[http://dx.doi.org/10.1016/j.breast.2023.01.005] [PMID: 36669993]

Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N.T.; Prat, A.; Chae, Y.S.; Lee, K.S.; Niikura, N.; Park, Y.H.; Xu, B.; Wang, X.; Gil-Gil, M.; Li, W.; Pierga, J.Y.; Im, S.A.; Moore, H.C.F.; Rugo, H.S.; Yerushalmi, R.; Zagouri, F.; Gombos, A.; Kim, S.B.; Liu, Q.; Luo, T.; Saura, C.; Schmid, P.; Sun, T.; Gambhire, D.; Yung, L.; Wang, Y.; Singh, J.; Vitazka, P.; Meinhardt, G.; Harbeck, N.; Cameron, D.A. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med., 2022, 387(1), 9-20.
[http://dx.doi.org/10.1056/NEJMoa2203690] [PMID: 35665782]

Zhang, H.; Karakas, C.; Tyburski, H.; Turner, B.M.; Peng, Y.; Wang, X.; Katerji, H.; Schiffhauer, L.; Hicks, D.G. HER2-low breast cancers: Current insights and future directions. Semin. Diagn. Pathol., 2022, 39(5), 305-312.
[http://dx.doi.org/10.1053/j.semdp.2022.07.003] [PMID: 35872032]

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer (Accessed on 27 February 2023).

Abuhelwa, Z.; Alloghbi, A.; Alqahtani, A.; Nagasaka, M. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: A systematic review. Drugs, 2022, 82(9), 979-987.
[http://dx.doi.org/10.1007/s40265-022-01736-w] [PMID: 35759121]

Rugo, H.S.; Crossno, C.L.; Gesthalter, Y.B.; Kelley, K.; Moore, H.B.; Rimawi, M.F.; Westbrook, K.E.; Buys, S.S. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer. JCO Oncol. Pract., 2023, 19(8), 539-546.
[http://dx.doi.org/10.1200/OP.22.00480] [PMID: 37207306]

Soares, L.R.; Vilbert, M.; Rosa, V.D.L.; Oliveira, J.L.; Deus, M.M.; Freitas-Junior, R. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: A systematic review and single-arm meta-analysis. ESMO Open, 2023, 8(4), 101613.
[http://dx.doi.org/10.1016/j.esmoop.2023.101613] [PMID: 37481956]

Crimini, E.; Tini, G.; Tarantino, P.; Ascione, L.; Repetto, M.; Beria, P.; Ranghiero, A.; Marra, A.; Belli, C.; Criscitiello, C.; Esposito, A.; Guerini Rocco, E.; Barberis, M.C.P.; Mazzarella, L.; Curigliano, G. Evaluation of the geographical accessibility of genome-matched clinical trials on a national experience. Oncologist, 2023, oyad229.
[http://dx.doi.org/10.1093/oncolo/oyad229] [PMID: 37669224]

Meattini, I.; Poortmans, P.M.P.; Marrazzo, L.; Desideri, I.; Brain, E.; Hamaker, M.; Lambertini, M.; Miccinesi, G.; Russell, N.; Saieva, C.; Strnad, V.; Visani, L.; Kaidar-Person, O.; Livi, L. Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598 – EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. J. Geriatr. Oncol., 2021, 12(2), 182-189.
[http://dx.doi.org/10.1016/j.jgo.2020.07.013] [PMID: 32739355]

Botticelli, A.; Scagnoli, S.; Conte, P.; Cremolini, C.; Ascierto, P.A.; Cappuzzo, F.; Aglietta, M.; Mazzuca, F.; Capoluongo, E.; Blandino, G.; Malapelle, U.; Nuti, M.; D’Amati, G.; Cerbelli, B.; Pruneri, G.; Biffoni, M.; Giannini, G.; Cognetti, F.; Curigliano, G.; Marchetti, P. Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial. J. Clin. Oncol., 2022, 40(16_suppl)(Suppl.), 3087-3087.
[http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.3087]

Gianni, L.; Pienkowski, T.; Im, Y.H.; Roman, L.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Staroslawska, E.; de la Haba-Rodriguez, J.; Im, S.A.; Pedrini, J.L.; Poirier, B.; Morandi, P.; Semiglazov, V.; Srimuninnimit, V.; Bianchi, G.; Szado, T.; Ratnayake, J.; Ross, G.; Valagussa, P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol., 2012, 13(1), 25-32.
[http://dx.doi.org/10.1016/S1470-2045(11)70336-9] [PMID: 22153890]

Bianchini, G.; Kiermaier, A.; Bianchi, G.V.; Im, Y.H.; Pienkowski, T.; Liu, M.C.; Tseng, L.M.; Dowsett, M.; Zabaglo, L.; Kirk, S.; Szado, T.; Eng-Wong, J.; Amler, L.C.; Valagussa, P.; Gianni, L. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res., 2017, 19(1), 16.
[http://dx.doi.org/10.1186/s13058-017-0806-9] [PMID: 28183321]

Lemieux, J.; Clemons, M.; Provencher, L.; Dent, S.; Latreille, J.; Mackey, J.; Pritchard, K.I.; Rayson, D.; Verma, S.; Verma, S.; Wang, B.; Chia, S. The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr. Oncol., 2009, 16(5), 48-57.
[http://dx.doi.org/10.3747/co.v16i5.510] [PMID: 19862361]

Swain, S.M.; Kim, S.B.; Cortés, J.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Knott, A.; Clark, E.; Ross, G.; Benyunes, M.C.; Baselga, J. Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol., 2013, 14(6), 461-471.
[http://dx.doi.org/10.1016/S1470-2045(13)70130-X] [PMID: 23602601]

Swain, S.M.; Miles, D.; Kim, S-B.; Im, Y.-H; Im, S.-A.; Semiglazov, V. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol., 2020, 21, 519-530.

Bachelot, T.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Bondarenko, I.; Paluch-Shimon, S.; Wardley, A.; Merot, J.L.; du Toit, Y.; Easton, V.; Lindegger, N.; Miles, D.; Bouzid, K.; Campone, M.; Coudert, B.; Nowecki, Z.; Errihani, H.; Dalenc, F.; Ferreira, A.; Mano, M.; Ricci, F.; Kalofonos, H.; Andreetta, C.; Montemurro, F.; Barrett, S.; Zhang, Q.; Mavroudis, D.; Matus, J.; Beato, C.; Hu, X.; Gaafar, R.; Abdel Azeem, H.; Perrin, C.; Ettl, J.; Lang, I.; Verma, S.; Li, H.; Brain, E.; Hoffmann, O.; Cariello, A.; Tondini, C.; Altwegeiri, T.; Loman, N.; Lux, M.; Frassoldati, A.; Aziz, Z.; Salas, F.; Streb, J.; Wronski, A.; Menjón Beltrán, S.; Cicin, I.; Schmid, P.; Laing, R.; Tong, Z.; Boer, K.; Juhasz, B.; Gianni, L.; Curigliano, G.; Juarez, A.; Susnjar, S.; Matos, E.; Uslu, R.; Wildiers, H.; Cruz, M.; Bourgeois, H.; von Schumann, R.; Stemmer, S.; Vásquez, F.M.; Dominguez, A.; Wojtukiewicz, M.; Trifunovic, J.; Illarramendi, J.J.; Garcia, L.; Peron, Y.I.; Echarri, M.J.; Voitko, N.; Wheatley, D.; Waters, S.; De Boer, R.; Jerusalem, G.; Cocquyt, V.; Barrios, C.; Panasci, L.; Mattson, J.; Tanner, M.; Gozy, M.; Vasilopoulos, G.; Revesz, J.; Latini, L.; Gridelli, C.; Lazaro, J.; Gonzalez, A.; Barnadas Molins, A.; Martinez, E.; Alarcón, J.; Arance, A.; Klint, L.; Kovalyov, O.; Baird, R.; Yeo, B.; McCarthy, N.; Greil, R.; Wang, S.; Artignan, X.; Augereau, P.; Juhasz-Boess, I.; Ngan, R.; Goldberg, H.; Di Costanzo, F.; Ferraù, F.; Aleknavicius, E.; Rashid, K.; Costa, L.; Angel Garcia, J.; de la Cruz, L.R.; López López, R.; Del Val, O.; Ozyilkan, O.; Azribi, F.; Verrill, M.; Turner, N.; Beith, J.; Petzer, A.; Andrade, J.; Bernstein, V.; Rayson, D.; Saad Eldin, I.; Achille, M.; Mueller, V.; Gennari, A.; Cascinu, S.; Ghosn, M.; El-Saghir, N.; Van den Bosch, J.; Oosterkamp, R.; Kukulska, M.; Pelaez, I.; Hernandez, C.; del Mar Gordon, M.; Dalmau, E.; Alonso, J.L.; Aksoy, S.; Coskun, H.S.; Shparyk, Y.; Varughese, M.; Panwar, U.; Barraclough, L.; Levitt, N.; Hicks, J.; Rigg, A.; Allen, M.; Castillo, C.; Fein, L.E.; Stuart-Harris, R.; Singer, C.; Stoeger, H.; Smiljanic, S.; Feng, J.; Cedeño, M.; Berdah, J.F.; Orfeuvre, H.; Goncalves, A.; Grischke, E-M.; Simon, E.; Wagner, S.; Efremidou, A.; Papazisis, K.; Evron, E.; Inbar, M.; Baruch, N.B.; Geffen, D.; Karminsky, N.; Ruggeri, E.M.; Luigi, C.; Grasso, D.; Juozaityte, E.; Rafael Rodriguez Cid, J.; Roerdink, H.; Siddiqi, N.; Passos Coelho, J.L.; Garre, E.G.; Garcia, A.; Martínez Jañez, N.; Lopez Ceballos, M.H.; Mele, M.; García, M.; Arcediano, A.; McAdam, K.; Perren, T.; Hicks, J.; Taylor, W.; Humphreys, A.; Vera, R.; Kaen, L.A.; Steger, G.; Andel, J.; de Grève, J.; Huizing, M.; Hegg, R.; Joy, A.; Sehdev, S.; Kütner, R.; Ruohola, J.; Dohollou, N.; Grosjean, J.; Laplaige, P.; Largillier, R.; Martin, P.; Pottier, V.; Alexandre, J.; Christensen, B.; Zahm, D-M.; Khandan, F.; Lueck, H-J.; Fountzilas, G.; Fried, G.; Giacobino, A.; Bonetti, A.; Guerra, Y.C.; Van Warmerdam, L.; Van der Velden, A.; Vrijaldenhoven, S.; de Jongh, F.; Cavero, M.; Andres Conejero, R.; Murias, A.; Saura, S.; Oltra, A.; Redondo, A.; Ribelles, N.; Bachmeier, K.; Joffe, J.; Chakraborti, P.; Beresford, M.; Butt, M.; Poole, C.; Yordi, G.; Woodward, N.; Amorim, G.; Califaretti, N.; Fox, S.; Robidoux, A.; Li, N.L.; Li, N.; Jiang, J.; Soria, T.; Padrik, P.; Saarni, O.; Genet, D.; Catala, S.; Barletta, H.; Teixeira, L.; Facchini, T.; Hesse, T.; Kühn, T.; Ober, A.; Repp, R.; Schroeder, W.; Pectasides, D.; Bodoky, G.; Kahan, Z.; Jiveliouk, I.; Rosengarten, O.; Alabiso, O.; Perez, M.; Van de Wouw, Y.; Smok-Kalwat, J.; Damasceno, M.; Sousa, G.; Abulkhair, O.; Antón Torres, A.; Martinez, M.P.; Garcia Mata, J.; Jesús Florián Jerico, M.S.; Llombart, A.; Sanchez, R.; Torrego, J.C.; Garate, C.O.; Rodriguez, C.; Llorente, R.; de Prado, D.S.; Cortés, J.; Llorca, C.; Galán, A.; Viñas Villaro, G.; Narbe, U.; Bjömeklett, H.G.; Westwell, S.; Newby, J.; Jafri, M.; Rodríguez, R.; Alonso, I. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann. Oncol., 2019, 30(5), 766-773.
[http://dx.doi.org/10.1093/annonc/mdz061] [PMID: 30796821]

Miles, D.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Campone, M.; Bondarenko, I.; Nowecki, Z.; Errihani, H.; Paluch-Shimon, S.; Wardley, A.; Merot, J.L.; Trask, P.; du Toit, Y.; Pena-Murillo, C.; Revelant, V.; Klingbiel, D.; Bachelot, T.; Bachelot, T.; Bouzid, K.; Campone, M.; Desmoulins, I.; Coudert, B.; Bondarenko, I.; Nowecki, Z.; Glogowska, I.; Ciruelos Gil, E.; Errihani, H.; Dalenc, F.; Ricci, F.; Dieras, V.; Kaufman, B.; Paluch-Shimon, S.; Wardley, A.; Schneeweiss, A.; Ferreira, A.; Mano, M.; Kalofonos, H.; Andreetta, C.; Puglisi, F.; Montemurro, F.; Barrett, S.; Zhang, Q.; Mavroudis, D.; Matus, J.; Villarreal Garza, C.; Beato, C.; Ismael, G.; Hu, X.; Abdel Azeem, H.; Gaafar, R.; Perrin, C.; Kerbrat, P.; Ettl, J.; Paepke, S.; Hitre, E.; Lang, I.; Trudeau, M.; Verma, S.; Li, H.; Hoffmann, O.; Aktas, B.; Cariello, A.; Cruciani, G.; Tienghi, A.; Tondini, C.; Al-Twegieri, T.; Loman, N.; Laing, R.; Miles, D.; Brain, E.; Fasching, P.; Lux, M.; Frassoldati, A.; Aziz, Z.; Salas, J.; Streb, J.; Krzemieniecki, K.; Wronski, A.; Garcia Garcia, J.; Menjon Beltran, S.; Cicin, I.; Schmid, P.; Gallagher, C.; Turner, N.; Tong, Z.; Boer, K.; Juhász, B.; Horvath, Z.; Bianchini, G.; Gianni, L.; Curigliano, G.; Juarez Ramiro, A.; Susnjar, S.; Matos, E.; Sevillano, E.; Garcia Estevez, L.; Gokmen, E.; Uslu, R.; Wildiers, H.; Schutz, F.; Cruz, M.; Bourgeois, H.; von Schumann, R.; Stemmer, S.; Dominguez, A.; Morales-Vásques, F.; Wojtukiewicz, M.; Trifunovic, J.; Echarri Gonzalez, M.J.; Illarramendi Mañas, J.; Martinez De Dueñas, E.; Voitko, N.; Hicks, J.; Waters, S.; Barrett-Lee, P.; Wheatley, D.; De Boer, R.; Cocquyt, V.; Jerusalem, G.; Barrios, C.; Panasci, L.; Mattson, J.; Tanner, M.; Gozy, M.; Vasilopoulos, G.; Papandreou, C.; Revesz, J.; Battelli, N.; Benedetti, G.; Latini, L.; Gridelli, C.; Lazaro Leon, J.; Alarcón Company, J.; Arance Fernandez, A.; Barnadas Molins, A.; Calvo Plaza, I.; Bratos, R.; Gonzalez Martin, A.; Izarzugaza Peron, Y.; Klint, L.; Kovalev, A.; McCarthy, N.; Yeo, B.; Kee, D.; Thomson, J.; White, S.; Greil, R.; Wang, S.; Artignan, X.; Juhasz-Böess, I.; Rody, A.; Ngan, R.; Dourleshter, F.; Goldberg, H.; Doni, L.; Di Costanzo, F.; Ferraù, F.; Drobniene, M.; Aleknavicius, E.; Rashid, K.; Costa, L.; de la Cruz Merino, L.; Garcia Saenz, J.; López, R.; Del Val Munoz, O.; Ozyilkan, O.; Azribi, F.; Jaafar, H.; Baird, R.; Verrill, M.; Beith, J.; Petzer, A.; Moreira de Andrade, J.; Bernstein, V.; Macpherson, N.; Rayson, D.; Saad Eldin, I.; Achille, M.; Augereau, P.; Müller, V.; Rasco, A.; Evron, E.; Katz, D.; Berardi, R.; Cascinu, S.; De Censi, A.; Gennari, A.; El-Saghir, N.; Ghosn, M.; Oosterkamp, H.M.; Van den Bosch, J.; Kukulska, M.; Kalinka, E.; Alonso, J.; Dalmau Portulas, E.; Del Mar Gordon Santiago, M.; Pelaez Fernandez, I.; Aksoy, S.; Altundag, K.; Senol Coskun, H.; Bozcuk, H.; Shparyk, Y.; Barraclough, L.; Hicks, J.; Levitt, N.; Panwar, U.; Kelly, S.; Rigg, A.; Varughese, M.; Castillo, C.; Fein, L.; Malik, L.; Stuart-Harris, R.; Singer, C.; Stoeger, H.; Samonigg, H.; Feng, J.; Cedeño, M.; Ruohola, J.; Berdah, J-F.; Goncalves, A.; Orfeuvre, H.; Grischke, E-M.; Simon, E.; Wagner, S.; Koumakis, G.; Papazisis, K.; Ben Baruch, N.; Fried, G.; Geffen, D.; Karminsky, N.; Peretz, T.; Cavanna, L.; Pedrazzioli, P.; Grasso, D.; Ruggeri, E.; D’Auria, G.; Moscetti, L.; Juozaityte, E.; Rodriguez Cid, J.; Roerdink, H.; Siddiqi, N.; Passos Coelho, J.; Arcediano Del Amo, A.; Garcia Garre, E.; García Gonzalez, M.; Garcia-Palomo Perez, A.; Herenandez Perez, C.; Lopez Alvarez, P.; Lopez De Ceballos, M.H.; Martínez Jañez, N.; Mele Olive, M.; McAdam, K.; Perren, T.; Dunn, G.; Humphreys, A.; Taylor, W.; Vera, R.; Kaen, L.; Andel, J.; Steger, G.; De Grève, J.; Huizing, M.; Hegg, R.; Joy, A.; Kuruvilla, P.; Sehdev, S.; Smiljanic, S.; Kütner, R.; Alexandre, J.; Grosjean, J.; Laplaige, P.; Largillier, R.; Maes, P.; Martin, P.; Pottier, V.; Christensen, B.; Khandan, F.; Lück, H-J.; Zahm, D-M.; Papandreou, C.; Fountzilas, G.; Karavasilis, V.; Safra, T.; Inbar, M.; Ryvo, L.; Bonetti, A.; Seles, E.; Giacobino, A.; Chavarri Guerra, Y.; de Jongh, F.; van der Velden, A.; van Warmerdam, L.; Vrijaldenhoven, S.; Smorenburg, C.H.; Cavero, M.; Andres Conejero, R.; Oltra Ferrando, A.; Redondo Sanchez, A.; Ribelles Entrena, N.; Saura Grau, S.; Viñas Vilaro, G.; Bachmeier, K.; Beresford, M.; Butt, M.; Joffe, J.; Poole, C.; Woodings, P.; Chakraborti, P.; Yordi, G.; Woodward, N.; Nobre, A.; Luiz Amorim, G.; Califaretti, N.; Fox, S.; Robidoux, A.; Li, E.; Li, N.; Jiang, J.; Soria, T.; Padrik, P.; Lahdenpera, O.; Barletta, H.; Dohollou, N.; Genet, D.; Prulhiere, K.; Coeffic, D.; Facchini, T.; Vieillot, S.; Catala, S.; Teixeira, L.; Hesse, T.; Kühn, T.; Ober, A.; Repp, R.; Schröder, W.; Pectasides, D.; Bodoky, G.; Kahan, Z.; Jiveliouk, I.; Rosengarten, O.; Rossi, V.; Alabiso, O.; Pérez Martínez, M.; van de Wouw, A.J.; Smok-Kalwat, J.; Damasecno, M.; Augusto, I.; Sousa, G.; Saadein, A.; Abdelhafiez, N.; Abulkhair, O.; Antón Torres, A.; Corbellas Aparicio, M.; Llorente Domenech, R.; Florián Jerico, J.; Garcia Mata, J.; Gil Raga, M.; Galan Brotons, A.; Llombart Cussac, A.; Llorca Ferrandiz, C.; Martinez Del Prado, P.; Olier Garate, C.; Rodriguez Sanchez, C.; Sanchez Gomez, R.; Santisteban Eslava, M.; Soberino, J.; Vidal Losada Garcia, M.; Soto de Prado, D.; Torrego Garcia, J.; Vicente Rubio, E.; Garcia, M.; Murias Rosales, A.; Granstam Björneklett, H.; Narbe, U.; Jafri, M.; Rea, D.; Newby, J.; Jones, A.; Westwell, S.; Ring, A.; Alonso, I.; Rodríguez, R. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann. Oncol., 2021, 32(10), 1245-1255.
[http://dx.doi.org/10.1016/j.annonc.2021.06.024] [PMID: 34224826]

Schneeweiss, A.; Chia, S.; Hickish, T.; Harvey, V.; Eniu, A.; Waldron-Lynch, M.; Eng-Wong, J.; Kirk, S.; Cortés, J. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur. J. Cancer, 2018, 89, 27-35.
[http://dx.doi.org/10.1016/j.ejca.2017.10.021] [PMID: 29223479]

Squires, H.; Pandor, A.; Thokala, P.; Stevens, J.W.; Kaltenthaler, E.; Clowes, M.; Coleman, R.; Wyld, L. Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: An evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 2018, 36(1), 29-38.
[http://dx.doi.org/10.1007/s40273-017-0556-7] [PMID: 28770452]

Piccart, M.; Procter, M.; Fumagalli, D.; De Azambuja, E.; Clark, E.; Ewer, M.S. Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable her2-positive early breast cancer. Gen. Sess. Abstr., 2020, 80, GS1-GS04.

Bines, J.; Clark, E.; Barton, C.; Restuccia, E.; Procter, M.; Sonnenblick, A.; Fumagalli, D.; Parlier, D.; Arahmani, A.; Baselga, J.; Viale, G.; Reaby, L.L.; Frank, E.; Gelber, R.D.; Piccart, M.; Jackisch, C.; Petersen, J.A. Patient-reported function, health-related quality of life, and symptoms in APHINITY: Pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br. J. Cancer, 2021, 125(1), 38-47.
[http://dx.doi.org/10.1038/s41416-021-01323-y] [PMID: 33828257]

de Azambuja, E.; Agostinetto, E.; Procter, M.; Eiger, D.; Pondé, N.; Guillaume, S.; Parlier, D.; Lambertini, M.; Desmet, A.; Caballero, C.; Aguila, C.; Jerusalem, G.; Walshe, J.M.; Frank, E.; Bines, J.; Loibl, S.; Piccart-Gebhart, M.; Ewer, M.S.; Dent, S.; Plummer, C.; Suter, T. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open, 2023, 8(1), 100772.
[http://dx.doi.org/10.1016/j.esmoop.2022.100772] [PMID: 36681013]

Rimawi, M.; Ferrero, J.M.; de la Haba-Rodriguez, J.; Poole, C.; De Placido, S.; Osborne, C.K.; Hegg, R.; Easton, V.; Wohlfarth, C.; Arpino, G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial. J. Clin. Oncol., 2018, 36(28), 2826-2835.
[http://dx.doi.org/10.1200/JCO.2017.76.7863] [PMID: 30106636]

Bartsch, R. SABCS 2020: Update on triple-negative and metastatic HER2-positive breast cancer. Mag. Eur. Med. Oncol., 2021, 14(3), 247-251.
[http://dx.doi.org/10.1007/s12254-021-00722-4] [PMID: 34221179]

Arpino, G.; de la Haba-Rodriguez, J.; Ferrero, J.M.; De Placido, S.; Klingbiel, D.; Revelant, V.; Wohlfarth, C.; Poppe, R.; Rimawi, M.F. Abstract PD3-02: Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. Cancer Res., 2021, 81(4_Supplement)(Suppl.), PD3-02.
[http://dx.doi.org/10.1158/1538-7445.SABCS20-PD3-02]

Wildiers, H.; Tryfonidis, K.; Dal Lago, L.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Altintas, S.; Touati, N.; Cardoso, F.; Brain, E. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): An open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol., 2018, 19(3), 323-336.
[http://dx.doi.org/10.1016/S1470-2045(18)30083-4] [PMID: 29433963]

Wildiers, H.; Meyskens, T.; Marréaud, S.; Lago, L.D.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Meulemans, B.; Sousa, B.; Poncet, C.; Brain, E. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 2022, 64, 100-111.
[http://dx.doi.org/10.1016/j.breast.2022.05.004] [PMID: 35636341]

Wildiers, H.; Marreaud, S.; Lago, L.D.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Meulemans, B.; Sousa, B.; Poncet, C.; Brain, E. Abstract P1-18-06: Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer, followed by T-DM1 after progression. Cancer Res., 2022, 82(4_Supplement)(Suppl.), P1-18-06.
[http://dx.doi.org/10.1158/1538-7445.SABCS21-P1-18-06]

Hurvitz, S.A.; Martin, M.; Symmans, W.F.; Jung, K.H.; Huang, C.S.; Thompson, A.M.; Harbeck, N.; Valero, V.; Stroyakovskiy, D.; Wildiers, H.; Campone, M.; Boileau, J.F.; Beckmann, M.W.; Afenjar, K.; Fresco, R.; Helms, H.J.; Xu, J.; Lin, Y.G.; Sparano, J.; Slamon, D. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol., 2018, 19(1), 115-126.
[http://dx.doi.org/10.1016/S1470-2045(17)30716-7] [PMID: 29175149]

de Haas, S.L.; Slamon, D.J.; Martin, M.; Press, M.F.; Lewis, G.D.; Lambertini, C.; Prat, A.; Lopez-Valverde, V.; Boulet, T.; Hurvitz, S.A. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: An open-label, phase III study (KRISTINE). Breast Cancer Res., 2023, 25(1), 2.
[http://dx.doi.org/10.1186/s13058-022-01587-z] [PMID: 36631725]

Tolaney, S.M.; Tayob, N.; Dang, C.; Yardley, D.A.; Isakoff, S.J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A.C.; Reeder-Hayes, K.; Rugo, H.S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V.K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A.M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R.C.; Rimawi, M.; Abramson, V.; Pohlmann, P.R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K.; Zheng, Y.; Rosenberg, S.M.; Gelber, R.D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E.P.; Krop, I. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): A randomized clinical trial. J. Clin. Oncol., 2021, 39(21), 2375-2385.
[http://dx.doi.org/10.1200/JCO.20.03398] [PMID: 34077270]

Bellon, J.R.; Tayob, N.; Yang, D.D.; Tralins, J.; Dang, C.T.; Isakoff, S.J.; DeMeo, M.; Burstein, H.J.; Partridge, A.H.; Winer, E.P.; Krop, I.E.; Tolaney, S.M. Local therapy outcomes and toxicity from the ATEMPT Trial (TBCRC 033): A phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2022, 113(1), 117-124.
[http://dx.doi.org/10.1016/j.ijrobp.2021.12.173] [PMID: 34990776]

Barroso-Sousa, R.; Tarantino, P.; Tayob, N.; Dang, C.; Yardley, D.A.; Isakoff, S.J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A.C.; Reeder-Hayes, K.; Rugo, H.S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V.K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A.M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R.C.; Rimawi, M.; Abramson, V.; Pohlmann, P.R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K.J.; Zheng, Y.; Rosenberg, S.M.; Gelber, R.D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E.P.; Krop, I.; Tolaney, S.M. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): A randomized controlled trial. NPJ Breast Cancer, 2022, 8(1), 18.
[http://dx.doi.org/10.1038/s41523-022-00385-2] [PMID: 35173164]

Curigliano, G.; Mueller, V.; Borges, V.; Hamilton, E.; Hurvitz, S.; Loi, S.; Murthy, R.; Okines, A.; Paplomata, E.; Cameron, D.; Carey, L.A.; Gelmon, K.; Hortobagyi, G.N.; Krop, I.; Loibl, S.; Pegram, M.; Slamon, D.; Ramos, J.; Feng, W.; Winer, E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann. Oncol., 2022, 33(3), 321-329.
[http://dx.doi.org/10.1016/j.annonc.2021.12.005] [PMID: 34954044]

Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.A.; Lee, K.S.; Hurvitz, S.A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med., 2020, 382(7), 610-621.
[http://dx.doi.org/10.1056/NEJMoa1914510] [PMID: 31825192]

Markham, A. Margetuximab: First approval. Drugs, 2021, 81(5), 599-604.
[http://dx.doi.org/10.1007/s40265-021-01485-2] [PMID: 33761116]

MARGetuximab Or Trastuzumab (MARGOT) (MARGOT). 2023. Available from: https://beta.clinicaltrials.gov/study/NCT04425018?tab=results (Accessed on 10 April 2023).

Dang, C.; Ewer, M.S.; Delaloge, S.; Ferrero, J.M.; Colomer, R.; de la Cruz-Merino, L.; Werner, T.L.; Dadswell, K.; Verrill, M.; Eiger, D.; Sarkar, S.; de Haas, S.L.; Restuccia, E.; Swain, S.M. BERENICE final analysis: Cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early breast cancer. Cancers, 2022, 14(11), 2596.
[http://dx.doi.org/10.3390/cancers14112596] [PMID: 35681574]

Miglietta, F.; Pronzato, P.; Girardi, F.; Griguolo, G.; Guarneri, V.; Pappagallo, G.; Conte, P. Residual risk of relapse: a systematic review and a consensus project on unmet needs for HER2-positive non metastatic breast cancer patients. Eur. J. Cancer, 2022, 175, S57-S58.
[http://dx.doi.org/10.1016/S0959-8049(22)01504-0]

Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Grischke, E.M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; von Schumann, R.; Kates, R.; Kates, R.; Schumacher, J.; Wuerstlein, R.; Kreipe, H.H.; Harbeck, N. Comparison of neoadjuvant Nab-Paclitaxel + Carboplatin vs Nab-Paclitaxel + Gemcitabine in triple-negative breast cancer: Randomized WSG-ADAPT-TN trial results. J. Natl. Cancer Inst., 2018, 110(6), 628-637.
[http://dx.doi.org/10.1093/jnci/djx258] [PMID: 29228315]

Kolberg-Liedtke, C.; Feuerhake, F.; Garke, M.; Christgen, M.; Kates, R.; Grischke, E.M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Kuemmel, S.; Wuerstlein, R.; Graeser, M.; Nitz, U.; Kreipe, H.; Gluz, O.; Harbeck, N. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Res., 2022, 24(1), 58.
[http://dx.doi.org/10.1186/s13058-022-01552-w] [PMID: 36056374]

Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnak, A.B.; Weaver, R.; Traina, T.; Dalenc, F.; Aftimos, P.; Lynce, F.; Diab, S.; Cortés, J.; O’Shaughnessy, J.; Diéras, V.; Ferrario, C.; Schmid, P.; Carey, L.A.; Gianni, L.; Piccart, M.J.; Loibl, S.; Goldenberg, D.M.; Hong, Q.; Olivo, M.S.; Itri, L.M.; Rugo, H.S. ASCENT clinical trial investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med., 2021, 384(16), 1529-1541.
[http://dx.doi.org/10.1056/NEJMoa2028485] [PMID: 33882206]

Cejuela, M.; Vethencourt, A.; Pernas, S. Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer. Curr. Oncol. Rep., 2022, 24(12), 1801-1819.
[http://dx.doi.org/10.1007/s11912-022-01339-4] [PMID: 36255603]

Nicolò, E.; Tarantino, P.; Curigliano, G. Biology and treatment of HER2-low breast cancer. Hematol. Oncol. Clin. North Am., 2023, 37(1), 117-132.
[http://dx.doi.org/10.1016/j.hoc.2022.08.013] [PMID: 36435605]

Fehrenbacher, L.; Cecchini, R.S.; Geyer, C.E., Jr; Rastogi, P.; Costantino, J.P.; Atkins, J.N.; Crown, J.P.; Polikoff, J.; Boileau, J.F.; Provencher, L.; Stokoe, C.; Moore, T.D.; Robidoux, A.; Flynn, P.J.; Borges, V.F.; Albain, K.S.; Swain, S.M.; Paik, S.; Mamounas, E.P.; Wolmark, N. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J. Clin. Oncol., 2020, 38(5), 444-453.
[http://dx.doi.org/10.1200/JCO.19.01455] [PMID: 31821109]

Carlino, F.; Diana, A.; Ventriglia, A.; Piccolo, A.; Mocerino, C.; Riccardi, F.; Bilancia, D.; Giotta, F.; Antoniol, G.; Famiglietti, V.; Feliciano, S.; Cangiano, R.; Lobianco, L.; Pellegrino, B.; De Vita, F.; Ciardiello, F.; Orditura, M. HER2-low status does not affect survival outcomes of patients with metastatic breast cancer (MBC) undergoing first-line treatment with endocrine therapy plus palbociclib: Results of a multicenter, retrospective cohort study. Cancers, 2022, 14(20), 4981.
[http://dx.doi.org/10.3390/cancers14204981] [PMID: 36291765]

AstraZeneca. A phase 3, randomized, multi-center, open-label study of trastuzumab deruxtecan (T-DXd) versus investigator’s choice chemotherapy in HER2-low, hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting (DESTINY-Breast06). Available from: https://clinicaltrials.gov/ct2/show/NCT04494425 (Accessed on 27 February 2023)

Gombos, A.; Goncalves, A.; Curigliano, G.; Bartsch, R.; Kyte, J.A.; Ignatiadis, M.; Awada, A. How I treat endocrine-dependent metastatic breast cancer. ESMO Open, 2023, 8(2), 100882.
[http://dx.doi.org/10.1016/j.esmoop.2023.100882] [PMID: 36806375]

Singh, B.; Olds, T.; Curtis, R.; Dumuid, D.; Virgara, R.; Watson, A.; Szeto, K.; O’Connor, E.; Ferguson, T.; Eglitis, E.; Miatke, A.; Simpson, C.E.M.; Maher, C. Effectiveness of physical activity interventions for improving depression, anxiety and distress: An overview of systematic reviews. Br. J. Sports Med., 2023, 57(18), 1203-1209.
[http://dx.doi.org/10.1136/bjsports-2022-106195] [PMID: 36796860]

Cowan, S.; Lim, S.; Alycia, C.; Pirotta, S.; Thomson, R.; Gibson-Helm, M.; Blackmore, R.; Naderpoor, N.; Bennett, C.; Ee, C.; Rao, V.; Mousa, A.; Alesi, S.; Moran, L. Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr. Disord., 2023, 23(1), 14.
[http://dx.doi.org/10.1186/s12902-022-01208-y] [PMID: 36647089]

Catalano, A. COVID-19: Could irisin become the handyman myokine of the 21^st century? Coronaviruses, 2020, 1(1), 32-41.
[http://dx.doi.org/10.2174/2666796701999200617154655]

Li, C.; Shang, S.; Liang, W. Physical activity types, physical activity levels and risk of diabetes in general adults: The NHANES 2007–2018. Int. J. Environ. Res. Public Health, 2023, 20(2), 1398.
[http://dx.doi.org/10.3390/ijerph20021398] [PMID: 36674154]

Fresno-Alba, S.; Denche-Zamorano, Á.; Pastor-Cisneros, R.; Pereira-Payo, D.; Franco-García, J.M.; Jiménez- Castuera, R. Breast cancer and physical activity: A bibliometric analysis. Front. Oncol., 2023, 12, 1051482.
[http://dx.doi.org/10.3389/fonc.2022.1051482] [PMID: 36713550]

Spei, M.E.; Samoli, E.; Bravi, F.; La Vecchia, C.; Bamia, C.; Benetou, V. Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival. Breast, 2019, 44, 144-152.
[http://dx.doi.org/10.1016/j.breast.2019.02.001] [PMID: 30780085]

Swain, C.T.V.; Drummond, A.E.; Boing, L.; Milne, R.L.; English, D.R.; Brown, K.A.; van Roekel, E.H.; Dixon- Suen, S.C.; Lynch, M.J.; Moore, M.M.; Gaunt, T.R.; Martin, R.M.; Lewis, S.J.; Lynch, B.M. Linking physical activity to breast cancer via sex hormones, part 1: The effect of physical activity on sex steroid hormones. Cancer Epidemiol. Biomarkers Prev., 2022, 31(1), 16-27.
[http://dx.doi.org/10.1158/1055-9965.EPI-21-0437] [PMID: 34670800]

De Placido, S.; Giuliano, M.; Schettini, F.; Von Arx, C.; Buono, G.; Riccardi, F.; Cianniello, D.; Caputo, R.; Puglisi, F.; Bonotto, M.; Fabi, A.; Bilancia, D.; Ciccarese, M.; Lorusso, V.; Michelotti, A.; Bruzzese, D.; Veneziani, B.M.; Locci, M.; De Laurentiis, M.; Arpino, G. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast, 2018, 38, 86-91.
[http://dx.doi.org/10.1016/j.breast.2017.12.012] [PMID: 29287189]

Perez, E.A.; López-Vega, J.M.; Petit, T.; Zamagni, C.; Easton, V.; Kamber, J.; Restuccia, E.; Andersson, M. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res., 2016, 18(1), 126.
[http://dx.doi.org/10.1186/s13058-016-0773-6] [PMID: 27955684]

Alam, M.M.; Rahman, T.; Afroz, Z.; Chakraborty, P.A.; Wahab, A.; Zaman, S.; Hawlader, M.D.H. Quality of Life (QoL) of cancer patients and its association with nutritional and performance status: A pilot study. Heliyon, 2020, 6(10), e05250.
[http://dx.doi.org/10.1016/j.heliyon.2020.e05250] [PMID: 33134577]

Sprangers, M.A.; Groenvold, M.; Arraras, J.I.; Franklin, J.; te Velde, A.; Muller, M.; Franzini, L.; Williams, A.; de Haes, H.C.; Hopwood, P.; Cull, A.; Aaronson, N.K. The european organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J. Clin. Oncol., 1996, 14(10), 2756-2768.
[http://dx.doi.org/10.1200/JCO.1996.14.10.2756] [PMID: 8874337]

Giesinger, J.M.; Loth, F.L.C.; Aaronson, N.K.; Arraras, J.I.; Caocci, G.; Efficace, F.; Groenvold, M.; van Leeuwen, M.; Petersen, M.A.; Ramage, J.; Tomaszewski, K.A.; Young, T.; Holzner, B. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J. Clin. Epidemiol., 2020, 118, 1-8.
[http://dx.doi.org/10.1016/j.jclinepi.2019.10.003] [PMID: 31639445]

Iacopetta, D.; Ceramella, J.; Catalano, A.; Saturnino, C.; Pellegrino, M.; Mariconda, A.; Longo, P.; Sinicropi, M.S.; Aquaro, S. COVID-19 at a glance: An up-to-date overview on variants, drug design and therapies. Viruses, 2022, 14(3), 573.
[http://dx.doi.org/10.3390/v14030573] [PMID: 35336980]

Bjelic-Radisic, V.; Cardoso, F.; Cameron, D.; Brain, E.; Kuljanic, K.; da Costa, R.A.; Conroy, T.; Inwald, E.C.; Serpentini, S.; Pinto, M.; Weis, J.; Morag, O.; Lindviksmoen Astrup, G.; Tomaszweksi, K.A.; Pogoda, K.; Sinai, P.; Sprangers, M.; Aaronson, N.; Velikova, G.; Greimel, E.; Arraras, J.; Bottomley, A.; Bleiker, E.; Bliem, B.; Chie, W.; Creutzberg, C.; Deville, V.; Duhoux, F.; Eilf, K.; Hartup, S.; Koller, M.; Nagele, E.; Nicolatou-Galitis, O.; Oberguggenberger, A.; Schmalz, C.; Winters, Z. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann. Oncol., 2020, 31(2), 283-288.
[http://dx.doi.org/10.1016/j.annonc.2019.10.027] [PMID: 31959345]

Chiesi, F.; Vizza, D.; Valente, M.; Bruno, R.; Lau, C.; Campagna, M.R.; Lo Iacono, M.; Bruno, F. Positive personal resources and psychological distress during the COVID-19 pandemic: Resilience, optimism, hope, courage, trait mindfulness, and self-efficacy in breast cancer patients and survivors. Support. Care Cancer, 2022, 30(8), 7005-7014.
[http://dx.doi.org/10.1007/s00520-022-07123-1] [PMID: 35579755]

Adams-Campbell, L.L.; Hicks, J.; Makambi, K.; Randolph-Jackson, P.; Mills, M.; Isaacs, C.; Dash, C. An 8-week exercise study to improve cancer treatment related fatigue and QOL among African American breast cancer patients undergoing radiation treatment: A pilot randomized clinical trial. J. Natl. Med. Assoc., 2023, 115(2), 199-206.
[http://dx.doi.org/10.1016/j.jnma.2023.01.011] [PMID: 36828705]

Cariolou, M.; Abar, L.; Aune, D.; Balducci, K.; Becerra- Tomás, N.; Greenwood, D.C.; Markozannes, G.; Nanu, N.; Vieira, R.; Giovannucci, E.L.; Gunter, M.J.; Jackson, A.A.; Kampman, E.; Lund, V.; Allen, K.; Brockton, N.T.; Croker, H.; Katsikioti, D.; McGinley-Gieser, D.; Mitrou, P.; Wiseman, M.; Cross, A.J.; Riboli, E.; Clinton, S.K.; McTiernan, A.; Norat, T.; Tsilidis, K.K.; Chan, D.S.M. Postdiagnosis recreational physical activity and breast cancer prognosis: Global cancer update programme (CUP global) systematic literature review and meta-analysis. Int. J. Cancer, 2023, 152(4), 600-615.
[http://dx.doi.org/10.1002/ijc.34324] [PMID: 36279903]

Murri, A.; Vitucci, D.; Tranchita, E.; Grazioli, E.; Gori, S.; Modena, A.; Turazza, M.; Filippini, R.; Galeazzi, S.; Verzè, M.; Frittelli, P.; Corsi, D.C.; Nicolis, F.; Parisi, A.; Cerulli, C. “OPERATION PHALCO” Adapted physical activity for breast cancer survivors: Is it time for a multidisciplinary approach? Cancers, 2022, 15(1), 34.
[http://dx.doi.org/10.3390/cancers15010034] [PMID: 36612031]